Ensitrelvir Fumaric Acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ensitrelvir Fumaric Acid Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
22
Registered trials
8
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ensitrelvir Fumaric Acid can convert its Small molecule drug profile and SARS-CoV-2 3CLpro biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ensitrelvir Fumaric Acid (query alias: ensitrelvir) |
|---|---|
| Modality / target | Small molecule drug; SARS-CoV-2 3CLpro; SARS-CoV-2 3CLpro inhibitors |
| Highest global status | Approved |
| Originator | Hokkaido University, Shionogi & Co., Ltd. |
| Active developers | Shionogi & Co., Ltd., Shionogi, Inc. |
The MCP disease footprint includes COVID-19, Inflammation, Post Acute COVID 19 Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCT2031250501 | Phase 3 | 募集中 | 40 | -Adverse events, laboratory tests, vital signs -Plasma concentration of ensitrelvir |
| JPRN-jRCT2031240587 | Phase 1 | Recruiting | 28 | 薬物動態パラメータ |
| NCT06775730 | Phase 1 | Completed | 24 | Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol (EE) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts
Phase 3; n=2031; evaluation: Positive. Reported fields: AE = 15.5 % ; AE = 15.1 %
Placebo-Controlled, Randomized Trial of Ensitrelvir (S-217622) for Viral Persistence and Inflammation in People Experiencing Long COVID (PREVAIL-LC)
Phase 2; n=40; evaluation: not stated. Reported fields: Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Physical Health Summary Score(Mean) = 41.6 score on a scale (95% Confidence Interval, 39.7 - 43.4); Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Physical Health Summary Score(Mean) = 43.6 score on a scale (95% Confidence Interval, 41.7 - 45.4); -
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Phase 2; n=604; evaluation: Positive. Reported fields: Viral clearance = Viral clearance following ensitrelvir was 82% faster (95% credible interval 61-104) than no study drug and 16% slower (5-25) than ritonavir-boosted nirmatrelvir. ; Viral clearance = Viral clearance following ensitrelvir was 82% faster (95% credible interval 61-104) than no study drug and 16% slower (5-25) than ritonavir-boosted nirmatrelvir.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ensitrelvir Fumaric Acid addresses COVID-19, Inflammation, Post Acute COVID 19 Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-12-19 | Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Juniper Therapeutics and SAR approval in Singapore regarding ensitrelvir fumaric acid, a treatment drug for the novel coronavirus infection (COVID-19) | Approved | Financial terms not disclosed |
| 2022-12-29 | Chia Tai Tianqing will promote the use of Ping An-Shionogi's ensitrelvir fumaric acid for COVID-19 treatment in China. | Approved | Financial terms not disclosed |
| 2022-12-23 | Ping An-Shionogi Signs a License Agreement with Shanghai Pharmaceutical for Import and Domestic Distribution of Ensitrelvir, a Therapeutic Drug for COVID-19 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
